HCA Q2 Revenue Tops $20.2B, but Uncompensated Care Surges and Cash Flow Drops
HCA sits 26% above its 52-week low of $331.61.
Summary
HCA Healthcare's Q2 2026 revenue grew 8.7% to $20.23B, but uncompensated care costs surged 29% and operating cash flow dropped 44%, confirming the pressures behind its recent guidance cut.
Key Events · Earnings and Guidance · HCA
-
Revenue Up, But Costs Bite
Q2 revenue rose 8.7% to $20.23B, but uncompensated care costs jumped 29% to $1.445B as uninsured admissions surged 23.3% after enhanced premium tax credits expired.
-
Cash Flow Deterioration
Operating cash flow fell 44% to $2.335B from $4.210B a year ago, driven by a $1.4B working capital drain and $594M higher tax payments.
-
Debt Load Increases
Total debt rose to $49.718B from $46.492B at year-end, with $3B in new senior notes issued in April, partly offset by $2.5B in redemptions.
-
Share Buybacks Continue
HCA repurchased $1.988B in stock during Q2 at an average price of $414.25, with $7.21B remaining under its $10B authorization.
Analysis · HCA · Industrial Applications And Services
HCA Healthcare delivered an 8.7% revenue increase to $20.23 billion in Q2 2026, yet the quarter exposed significant headwinds. Uncompensated care costs climbed 29% to $1.445 billion as uninsured admissions jumped 23% following the expiration of enhanced premium tax credits. Operating cash flow tumbled to $2.335 billion from $4.210 billion a year ago, pressured by working capital drains and higher tax payments. While the company continued aggressive share buybacks, debt rose to nearly $50 billion. The results confirm the guidance cut from two weeks ago, with rising uncompensated care and cash flow pressure now quantified.
At the time of this filing, HCA was trading at $417.50 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $92.8B. The 52-week trading range was $331.61 to $556.52. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.